Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study

BACKGROUND: Eribulin is a nontaxane microtubule inhibitor with activity in patients with metastatic breast cancer (MBC). We conducted a phase I dose-finding study of eribulin and capecitabine in patients with MBC pretreated with anthracycline and taxane. METHODS: Women with MBC aged ≤70 years were e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hattori, Masaya, Ishiguro, Hiroshi, Masuda, Norikazu, Yoshimura, Akiyo, Ohtani, Shoichiro, Yasojima, Hiroyuki, Morita, Satoshi, Ohno, Shinji, Iwata, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741785/
https://www.ncbi.nlm.nih.gov/pubmed/28861862
http://dx.doi.org/10.1007/s12282-017-0798-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741785/
https://www.ncbi.nlm.nih.gov/pubmed/28861862
http://dx.doi.org/10.1007/s12282-017-0798-4

Ejemplares similares